Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target
Esperion Therapeutics, Inc. +3.64%
Esperion Therapeutics, Inc. ESPR | 2.28 | +3.64% |
Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:
ESPR) with a Buy and maintains $8 price target.